Corrigendum to “A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non–Small Cell Lung Cancer Cells” [Neoplasia 18 (2016) 199-212]

The authors regret to have mistakenly placed the figure of body weight change in mice treated with different agents in PC9 cells (Figure 6A, right) with that of PC9/gef B4 cells (Figure 6B, right) during the art work. The corrected Figure 6 was attached below. The authors would like to apologize for any inconvenience caused.

Figure 6.

Antitumor activity of BO-1978 in EGFR mutant NSCLC xenografts. Aliquots of 5 × 10⁶ PC9 (A), PC9/gef B4 (B), H1650 (C), and H1975 (D) cells were subcutaneously implanted in nude mice. When tumor sizes reached approximately 100 mm³, the mice were treated with vehicle, BO-1978 (40 mg/kg, daily for 5 consecutive days), gefitinib (10 mg/kg, daily for 5 consecutive days), BO-1978 + gefitinib, or cisplatin (6 mg/kg, three times every 4 days). The tumor volumes and body weights were monitored at the indicated times.